Press Release
Ivy Brain Tumor Center to Present Multiple Abstracts and a Special Session on Innovative Clinical Trial Design at the 2024 European Association of Neuro-Oncology Annual Meeting
The Ivy Brain Tumor Center at Barrow Neurological Institute will present updated study results and a special session on clinical trial design at the 19th Meeting of the European Association of Neuro-Oncology (EANO), which will take place in Glasgow, Scotland, October 17-20, 2024.
Ivy Brain Tumor Center’s Dr. Nader Sanai Named Arizona Bioscience Researcher of the Year
Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, has been named the 2024 Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association. This prestigious honor recognizes Dr. Sanai's pioneering efforts and unwavering dedication to advancing new therapies for brain tumor patients, breaking new ground in the fight against this challenging disease.
First patient dosed in Phase 3 Gliofocus Study for newly diagnosed glioblastoma patients at the Ivy Brain Tumor Center
The Ivy Brain Tumor Center announced that the first patient has been dosed in the pivotal Phase 3 Gliofocus Study. Gliofocus is an open-label, randomized Phase 3 trial that will compare the efficacy of niraparib, a PARP1/2 selective inhibitor, to temozolomide head-to-head in adult patients with newly diagnosed MGMT-unmethylated glioblastoma.
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
The Ivy Brain Tumor Center has released promising Phase 0/2 clinical trial results for niraparib, showing a significant improvement in overall survival for newly diagnosed glioblastoma patients, with survival times nearly doubling to 20.3 months compared to standard care. These findings will be presented at the 2024 ASCO Annual Meeting. Encouraged by these results, GSK is supporting the initiation of a global Phase 3 trial to further evaluate niraparib versus standard care.
Ivy Brain Tumor Center Announces Promising Results of Phase 0/1 Glioblastoma Study at the American Association for Cancer Research Annual Meeting
The Ivy Brain Tumor Center announced initial results from a Phase 0/1b clinical trial of AZD1390, in combination with radiation therapy, in newly diagnosed, MGMT-unmethylated glioblastoma. Results from this study will be presented at the American Association for Cancer Research Annual Meeting and demonstrate that AZD1390 may be a potent radiosensitizer in both newly diagnosed and recurrent glioblastoma patients. Read the press release to learn more.
Ivy Brain Tumor Center Awarded U.S. Department of Defense Grant to Advance Promising Glioblastoma Drug Candidate
The Ivy Brain Tumor Center received a $1.48 million, three-year U.S. Department of Defense (DoD) Impact Award to advance the development of MnP3. This novel redox-active agent shows potential in the treatment of glioblastoma. Successful completion of the project will have a significant impact on translating the drug to clinical use.
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a collaborative Phase 0/2 trial of niraparib, supported by GSK, in patients with newly diagnosed glioblastoma with unmethylated MGMT.
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade Glioma
The Ivy Brain Tumor Center announced the first patient has been treated in a novel Phase 0/1 clinical trial of BDTX-1535, an experimental drug targeting oncogenic EGFR (epidermal growth factor receptor) mutations in patients with recurrent high-grade glioma.
Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress
The Ivy Brain Tumor Center announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia mutated (ATM) kinase inhibitor AZD1390 in recurrent glioblastoma in combination with radiation therapy.
Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery Method
In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced the initiation of a ground-breaking Phase 0 clinical trial that tests a new experimental drug delivery method called superselective intra-arterial infusion, or SSIAI. This innovative approach can deliver highly-concentrated doses of experimental drugs directly to the tumor, potentially bypassing the blood-brain barrier and minimizing systemic side effects.